ReNerve Limited Enters Strategic Agreement with NetCentrix Ventures to Expand into Indian Nerve Repair Market

ReNerve Limited (ASX: RNV) has partnered strategically with NetCentrix Ventures to expand into India’s rapidly growing healthcare market. The agreement focuses on obtaining regulatory approval for ReNerve’s flagship product, the NervAlign® Nerve Cuff, followed by a tailored commercialization strategy. NetCentrix Ventures, through its collaboration with Indian government bodies such as BRIC RGCB, will assist with the regulatory and distribution process.

India’s nerve repair market, valued at approximately US$115 million (AU$175 million), is projected to exceed US$270 million (AU$410 million) by 2030, with an 18.5% compound annual growth rate. Key growth drivers include rising healthcare investment, a growing middle class, and increasing trauma and diabetes-related nerve damage cases. ReNerve CEO Dr. Julian Chick stated that India is a strategic addition to its global expansion, complementing existing operations in Asia and the Middle East and offering a strong market fit for its cost-effective nerve repair technologies.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com